Skip to main content
. 2018 Oct 2;8:14713. doi: 10.1038/s41598-018-32922-0

Figure 3.

Figure 3

Purification of the Cdf79930 and its activity against ulvan. (A) Purification of Cdf79930 by size exclusion chromatography and SDS-PAGE analysis of the purified fractions: lane 1, molecular weight standard; lane 2, Cdf79930 fraction after immobilised metal affinity chromatography; lane 3, fraction 1 after size exclusion chromatography; and lane 4, fraction 2 after size exclusion chromatography. The picture of the SDS-PAGE gel was cropped; full gel picture is added as Fig. S7 in the Supplementary Information. (B) Michaelis-Menten plot of Cdf79930 with ulvan extracted from U. amoricana as substrate. Each point represents the average value of triplicate measurements, and the error bar indicate the standard error. The fitted Km and Vmax values are 0.77 mg ml−1 and 540 µg of reducing end equivalents of glucose ml−1 min−1 mg protein−1, respectively. (C) Substrate specificity of the novel ulvan lyase. Cdf79930 was incubated with 200 µg of each substrate and incubated for 60 minutes at 37 °C. Cdf79930 depolymerised both chondroitin sulphate and heparan sulphate. (D) Separation of end-products from the Cdf79930 action on ulvan using size exclusion chromatography.